TY - JOUR
T1 - Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination
AU - Jergović, Mladen
AU - Uhrlaub, Jennifer L.
AU - Watanabe, Makiko
AU - Bradshaw, Christine M.
AU - White, Lisa M.
AU - LaFleur, Bonnie J.
AU - Edwards, Taylor
AU - Sprissler, Ryan
AU - Worobey, Michael
AU - Bhattacharya, Deepta
AU - Nikolich-Žugich, Janko
N1 - Funding Information: Supported in part by the USPHS award R37 AG020719 and the Bowman Professorship in Medical Sciences to J.N.-Z. Funding Information: J.N.Ž. is co-chair of the scientific advisory board of and receives research funding from Young Blood Institute, Inc. Sana Biotechnology has licensed intellectual property of D.B. and Washington University in St. Louis. D.B. is a co-founder of Clade Therapeutics. B.J.L. has a financial interest in Cofactor Genomics, Inc. and Iron Horse Dx. The remaining authors declare no competing interests. Publisher Copyright: © 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Aging is associated with a reduced magnitude of primary immune responses to vaccination. mRNA-based SARS-CoV-2 vaccines have shown efficacy in older adults but virus variant escape is still unclear. Here we analyze humoral and cellular immunity against an early-pandemic viral isolate and compare that to the P.1 (Gamma) and B.1.617.2 (Delta) variants in two cohorts (<50 and >55 age) of mRNA vaccine recipients. We further measure neutralizing antibody titers for B.1.617.1 (Kappa) and B.1.595, with the latter SARS-CoV-2 isolate bearing the spike mutation E484Q. Robust humoral immunity is measured following second vaccination, and older vaccinees manifest cellular immunity comparable to the adult group against early-pandemic SARS-CoV-2 and more recent variants. More specifically, the older cohort has lower neutralizing capacity at 7-14 days following the second dose but equilibrates with the younger cohort after 2-3 months. While long-term vaccination responses remain to be determined, our results implicate vaccine-induced protection in older adults against SARS-CoV-2 variants and inform thinking about boost vaccination.
AB - Aging is associated with a reduced magnitude of primary immune responses to vaccination. mRNA-based SARS-CoV-2 vaccines have shown efficacy in older adults but virus variant escape is still unclear. Here we analyze humoral and cellular immunity against an early-pandemic viral isolate and compare that to the P.1 (Gamma) and B.1.617.2 (Delta) variants in two cohorts (<50 and >55 age) of mRNA vaccine recipients. We further measure neutralizing antibody titers for B.1.617.1 (Kappa) and B.1.595, with the latter SARS-CoV-2 isolate bearing the spike mutation E484Q. Robust humoral immunity is measured following second vaccination, and older vaccinees manifest cellular immunity comparable to the adult group against early-pandemic SARS-CoV-2 and more recent variants. More specifically, the older cohort has lower neutralizing capacity at 7-14 days following the second dose but equilibrates with the younger cohort after 2-3 months. While long-term vaccination responses remain to be determined, our results implicate vaccine-induced protection in older adults against SARS-CoV-2 variants and inform thinking about boost vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85130756921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130756921&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-022-30617-9
DO - https://doi.org/10.1038/s41467-022-30617-9
M3 - Article
C2 - 35610270
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 2891
ER -